Day: March 7, 2023

Paralyzed individuals with spinal cord injury will have unprecedented access to walking in everyday environments as they are no longer limited when encountering stairs and curbsReWalk Users Now Able to Access Stairs and Curbs in the US A paralyzed individual walks up the stairs to visit a friend’s home using her ReWalk Personal Exoskeleton.MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, March 07, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd., (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced today that its innovative ReWalk Personal Exoskeleton technology has received clearance from the Food and Drug Administration (“FDA”) for use on stairs and curbs...

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format. A live webcast of the presentation can be accessed here. A replay of the event will be available on the “Events” section of the Rain website after the conclusion of the event and will be archived on the Rain website at www.rainoncology.com. About Rain Oncology Inc.Rain Oncology Inc. is a late-stage precision oncology company...

Leverages recently launched Saber 4400’s powerful transport features and includes an open approach to seamlessly work across multi-vendor networks to enable end-to-end optical service orchestration and automation DALLAS, March 07, 2023 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of access, optical and cloud-controlled software solutions, today announced that it has further expanded its Cloud EDGE portfolio with the launch of DZS Xtreme Transport. Along with the DZS Xtreme Access and DZS Xtreme Mobile solutions, DZS Xtreme Transport helps communications service providers accelerate deployment and streamline management of differentiating new services over next-generation, high-bandwidth and low-latency optical broadband infrastructure. The DZS Xtreme Transport solution will be highlighted at the Optical Fiber Communication...

– Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session – – Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid eye disease program – WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida. An oral presentation...